Generated by AI
Invivyd, Inc. Common Stock is the equity of Invivyd, a biopharmaceutical company focused on developing and commercializing monoclonal antibody therapies for the prevention and treatment of serious viral infectious diseases. The company’s current work centers on antibody-based solutions for COVID-19 and other respiratory viruses, supported by a proprietary platform that combines viral surveillance, predictive modeling, and antibody engineering. Its marketed and clinical-stage programs include PEMGARDA (pemivibart) and additional antibody candidates being developed for viral threats such as COVID-19, RSV, and measles. Invivyd serves the healthcare and biotechnology markets by advancing specialized biologic products designed for patients with limited preventive or treatment options, particularly immunocompromised populations. The company is headquartered in New Haven, Connecticut.
Website205 Church Street
New Haven, CT, 06510
United States
The latest articles about IVVD.
Summary of Nov 18's posts. Generated by AI.
Summary of Oct 11's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Investors talking about IVVD also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.